Medidata Solutions, Inc. provides cloud-based solutions for life sciences worldwide. It offers the Medidata Clinical Cloud, a platform, pioneering analytics, and clinical technology for the development of new therapies. The company's platform solutions include data capture and management and trial planning and management. It also provides professional services, such as implementation, sponsor enablement, strategic consulting, partner and ongoing support, and e-learning and training. The company markets and sells its cloud-based solutions through a direct sales force, as well as through relationships with contract research organizations (CROs) and other strategic partners. It serves pharmaceutical, biotechnology, medical device, and diagnostics companies; academic research centers, government, and other non-profit organizations; and CROs and other entities engaged in clinical trials. Medidata Solutions, Inc. was founded in 1999 and is headquartered in New York, New York.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Prepackaged software
Sub-IndustryHealth Care Technology
SectorMedical
Current SymbolNASDAQ:MDSO
Previous Symbol
CUSIP58471A10
Phone212-918-1800
Debt
Debt-to-Equity Ratio0.15
Current Ratio2.52
Quick Ratio2.52
Price-To-Earnings
Trailing P/E Ratio84.40
Forward P/E Ratio84.40
P/E Growth4.28
Sales & Book Value
Annual Sales$545.53 million
Price / Sales8.05
Cash Flow$1.5378 per share
Price / Cash46.65
Book Value$8.51 per share
Price / Book8.43
Profitability
EPS (Most Recent Fiscal Year)$0.85
Net Income$44.38 million
Net Margins8.43%
Return on Equity10.70%
Return on Assets5.69%
Miscellaneous
Employees1,680
Outstanding Shares61,190,000
Market Cap$4.43 billion
OptionableOptionable
Medidata Solutions (NASDAQ:MDSO) Frequently Asked Questions
What is Medidata Solutions' stock symbol?
Medidata Solutions trades on the NASDAQ under the ticker symbol "MDSO."
How were Medidata Solutions' earnings last quarter?
Medidata Solutions Inc (NASDAQ:MDSO) issued its earnings results on Thursday, October, 18th. The company reported $0.42 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $0.36 by $0.06. The business had revenue of $163.41 million for the quarter, compared to analysts' expectations of $162.09 million. Medidata Solutions had a return on equity of 10.70% and a net margin of 8.43%. The company's quarterly revenue was up 17.6% on a year-over-year basis. During the same period in the previous year, the firm posted $0.33 EPS. View Medidata Solutions' Earnings History.
When is Medidata Solutions' next earnings date?
What guidance has Medidata Solutions issued on next quarter's earnings?
Medidata Solutions issued an update on its FY 2018 earnings guidance on Thursday, October, 18th. The company provided EPS guidance of $1.48-1.60 for the period, compared to the Thomson Reuters consensus EPS estimate of $1.57. The company issued revenue guidance of $624-648 million, compared to the consensus revenue estimate of $636.64 million.
What price target have analysts set for MDSO?
10 brokerages have issued 1 year price targets for Medidata Solutions' stock. Their predictions range from $74.00 to $93.00. On average, they expect Medidata Solutions' share price to reach $85.70 in the next year. This suggests a possible upside of 19.5% from the stock's current price. View Analyst Price Targets for Medidata Solutions.
What is the consensus analysts' recommendation for Medidata Solutions?
10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Medidata Solutions in the last year. There are currently 4 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Medidata Solutions.
Has Medidata Solutions been receiving favorable news coverage?
Media coverage about MDSO stock has trended somewhat positive recently, according to InfoTrie Sentiment. The research firm scores the sentiment of news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Medidata Solutions earned a media sentiment score of 1.9 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 7.0 out of 10, indicating that recent news coverage is likely to have an effect on the company's share price in the immediate future.
Who are some of Medidata Solutions' key competitors?
Some companies that are related to Medidata Solutions include Shopify (SHOP), Symantec (SYMC), Citrix Systems (CTXS), Splunk (SPLK), Synopsys (SNPS), Veeva Systems (VEEV), ANSYS (ANSS), TAKE-TWO INTERACTIVE SOFTWARE (TTWO), Cadence Design Systems (CDNS), Temenos (TMNSF), SS&C Technologies (SSNC), PTC (PTC), Tableau Software (DATA), Dropbox (DBX) and UBISOFT Entmt S/ADR (UBSFY).
Who are Medidata Solutions' key executives?
Medidata Solutions' management team includes the folowing people:
- Mr. Tarek A. Sherif, Co-Founder, Chairman & CEO (Age 56)
- Mr. Glen M. De Vries, Co-Founder, Pres & Director (Age 46)
- Mr. Rouven Bergmann, CFO & Chief Accounting Officer (Age 45)
- Mr. Michael I. Otner, Exec. VP, Gen. Counsel & Sec. (Age 47)
- Mr. Michael Pray, Exec. VP & GM of Global Sales (Age 52)
Who are Medidata Solutions' major shareholders?
Medidata Solutions' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (11.11%), Janus Henderson Group PLC (2.88%), Pictet Asset Management Ltd. (2.66%), American Century Companies Inc. (2.60%), Bank of New York Mellon Corp (2.49%) and JPMorgan Chase & Co. (2.19%). Company insiders that own Medidata Solutions stock include Carlos Dominguez, Lee Shapiro, Michael I Otner, Michael L Capone, Michael Pray, Robert Taylor, Rouven Bergmann, Steven Isaac Hirschfeld, Tarek Sherif and Vries Glen Michael De. View Institutional Ownership Trends for Medidata Solutions.
Which institutional investors are selling Medidata Solutions stock?
MDSO stock was sold by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., Wells Fargo & Company MN, BlackRock Inc., Jane Street Group LLC, Global Thematic Partners LLC, Bank of New York Mellon Corp, Brown Advisory Inc. and Janus Henderson Group PLC. Company insiders that have sold Medidata Solutions company stock in the last year include Carlos Dominguez, Lee Shapiro, Michael I Otner, Robert Taylor, Rouven Bergmann and Tarek Sherif. View Insider Buying and Selling for Medidata Solutions.
Which institutional investors are buying Medidata Solutions stock?
MDSO stock was purchased by a variety of institutional investors in the last quarter, including Polen Capital Management LLC, Credit Suisse AG, Alliancebernstein L.P., Nikko Asset Management Americas Inc., Sumitomo Mitsui Trust Holdings Inc., ARK Investment Management LLC, Royce & Associates LP and Rice Hall James & Associates LLC. View Insider Buying and Selling for Medidata Solutions.
How do I buy shares of Medidata Solutions?
Shares of MDSO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Medidata Solutions' stock price today?
One share of MDSO stock can currently be purchased for approximately $71.74.
How big of a company is Medidata Solutions?
Medidata Solutions has a market capitalization of $4.43 billion and generates $545.53 million in revenue each year. The company earns $44.38 million in net income (profit) each year or $0.85 on an earnings per share basis. Medidata Solutions employs 1,680 workers across the globe.
What is Medidata Solutions' official website?
How can I contact Medidata Solutions?
Medidata Solutions' mailing address is 350 HUDSON ST. 9TH FLOOR, NEW YORK NY, 10014. The company can be reached via phone at 212-918-1800 or via email at [email protected]
MarketBeat Community Rating for Medidata Solutions (NASDAQ MDSO)
MarketBeat's community ratings are surveys of what our community members think about Medidata Solutions and other stocks. Vote "Outperform" if you believe MDSO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MDSO will underperform the S&P 500 over the long term. You may vote once every thirty days.
